Friday 02 Dec, 2022 02:44 AM
Site map | Locate Us | Login
   Eicher Motors' CV sales rise by 20% YoY in Nov'22; exports record sharp contraction    TVS Motor records 2% YoY sales growth in Nov    Cosmo First gains on Rs 108-cr share buyback    Gensol Engg gains on bagging solar projects     M&M records sales of 58,303 vehicles in November 2022    Esab India Ltd leads losers in 'A' group    Maruti Suzuki total sales climb 14% YoY in November    Adani Green gains on raising JPY denominated refinancing facility     Dynemic Products Ltd Partly Paidup leads losers in 'B' group    Tata Motors records 21% YoY sales growth in November    Volumes spurt at Hatsun Agro Product Ltd counter    FMCG shares edge lower    Power stocks slide    Utilties shares fall    Polycab announces strategic partnership with Redington  
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Zydus Lifesciences arm gets 2 observations from USFDA
30-Sep-22   12:05 Hrs IST

The company said that the manufacturing facility at SEZ, Ahmedabad was inspected by United States Food and Drug Administration (US FDA) from 23 September 2022 to 29 September 2022.

At the end of the inspection, the pharmaceutical company was issued with two observations by the US drug regulator. None of the observations are related to data integrity, the drug maker stated.

The Ahmedabad manufacturing facility is set up for the animal health business which will cater to US and other regulated markets.

The pharma major added that it will address the observations within a stipulated timeline working with the regulators.

None of the observations are related to data integrity and management believes that they are addressable, the drug maker stated.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company's consolidated net profit fell 11.7% to Rs 518.3 crore on a 1.8% increase in total income from operations to Rs 4,072.7 crore in Q1 FY23 over Q1 FY22.

The scrip rose 0.55% to currently trade at Rs 385.65 on the BSE.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 23677908
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016  |  MCX : INZ000081736
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 12815 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. Saravana Stocks Pvt. Ltd